pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 46 | Non-oncology: 25 Oncology: 21 |
| Under Consideration for Negotiation | 22 | Non-oncology: 13 Oncology: 9 |
| Completed Negotiations | 898 | With Letter of Intent: 776 Without agreement: 122 |
| Negotiations That Were Not Pursued | 113 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Andembry | CSL Behring Canada Inc. | Hereditary Angioedema | |
| Zepzelca (active pTAP negotiation) | Jazz Pharmaceuticals Canada Inc. | For the treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy. | |
| Anzupgo | LEO Pharma Inc. | Chronic hand eczema | |
| Opzelura | Incyte Biosciences Canada Corporation | Atopic dermatitis | |
| Sarclisa | Sanofi Genzyme Canada | In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). | |
| Itovebi | Hoffmann-La Roche Ltd. | In combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor-positive (HR+) (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or meta | |
| Epuris | Cipher | Acne Vulgaris | |
| Quviviq | Idorsia Pharmaceuticals Canada Ltd. | Insomnia | |
| Rebyota | Ferring Canada Inc. | Clostridioides difficile infection, prevention | |
| Perjeta | Hoffmann-La Roche Ltd. | In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer | |
| Alyftrek | Vertex Pharmaceuticals (Canada) Incorporated | Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older | |
| Lyvdelzi | Gilead Sciences Canada Inc. | For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA. | |
| Ranvu | Apotex Inc. | Multiple Indications |